Fatal asthma after omalizumab and controller therapy discontinuation

Eur Ann Allergy Clin Immunol. 2018 Jul;50(5):235-236. doi: 10.23822/EurAnnACI.1764-1489.70. Epub 2018 Jul 24.

Authors

C Lombardi¹, M Cottini², G Passalacqua³

Affiliations

¹ Unità Dipartimentale di Allergologia-Immunologia Clinica e Malattie Apparato Respiratorio, Ente Ospedaliero Fondazione Poliambulanza, Brescia, Italy.
² National Healthcare System, private practice, Bergamo, Italy.
³ Allergy and Respiratory Diseases, University of Genoa, Genova, Italy.

PMID: 30039694
DOI: 10.23822/EurAnnACI.1764-1489.70

No abstract available

Keywords: alternaria; controller drug; discontinuation; fatal asthma; omalizumab.

Publication types

Case Reports
Letter

MeSH terms

Adult
Airway Obstruction
Anti-Allergic Agents / therapeutic use*
Asthma / diagnosis*
Autopsy
Disease Progression
Eosinophilia
Fatal Outcome
Female
Humans
Immunoglobulin E / metabolism
Neutrophil Infiltration
Omalizumab / therapeutic use*
Patient Preference
Respiratory Insufficiency
Severity of Illness Index
Withholding Treatment

Substances

Anti-Allergic Agents
Omalizumab
Immunoglobulin E